345 related articles for article (PubMed ID: 12788977)
1. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
Cher ML; Biliran HR; Bhagat S; Meng Y; Che M; Lockett J; Abrams J; Fridman R; Zachareas M; Sheng S
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7847-52. PubMed ID: 12788977
[TBL] [Abstract][Full Text] [Related]
2. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
3. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
4. Maspin reduces prostate cancer metastasis to bone.
Hall DC; Johnson-Pais TL; Grubbs B; Bernal R; Leach RJ; Padalecki SS
Urol Oncol; 2008; 26(6):652-8. PubMed ID: 18367129
[TBL] [Abstract][Full Text] [Related]
5. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
6. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells.
Abraham S; Zhang W; Greenberg N; Zhang M
J Urol; 2003 Mar; 169(3):1157-61. PubMed ID: 12576872
[TBL] [Abstract][Full Text] [Related]
7. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model.
Shi HY; Zhang W; Liang R; Abraham S; Kittrell FS; Medina D; Zhang M
Cancer Res; 2001 Sep; 61(18):6945-51. PubMed ID: 11559574
[TBL] [Abstract][Full Text] [Related]
8. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
[TBL] [Abstract][Full Text] [Related]
9. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis.
Tahmatzopoulos A; Sheng S; Kyprianou N
Oncogene; 2005 Aug; 24(34):5375-83. PubMed ID: 16007219
[TBL] [Abstract][Full Text] [Related]
10. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
11. Maspin is up-regulated in premalignant prostate epithelia.
Pierson CR; McGowen R; Grignon D; Sakr W; Dey J; Sheng S
Prostate; 2002 Dec; 53(4):255-62. PubMed ID: 12430137
[TBL] [Abstract][Full Text] [Related]
12. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells.
Sheng S; Carey J; Seftor EA; Dias L; Hendrix MJ; Sager R
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11669-74. PubMed ID: 8876194
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.
Bonfil RD; Dong Z; Trindade Filho JC; Sabbota A; Osenkowski P; Nabha S; Yamamoto H; Chinni SR; Zhao H; Mobashery S; Vessella RL; Fridman R; Cher ML
Am J Pathol; 2007 Jun; 170(6):2100-11. PubMed ID: 17525276
[TBL] [Abstract][Full Text] [Related]
14. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Swiercz R; Keck RW; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2001; 8(3):463-70. PubMed ID: 11295064
[TBL] [Abstract][Full Text] [Related]
15. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
Podgorski I; Linebaugh BE; Sameni M; Jedeszko C; Bhagat S; Cher ML; Sloane BF
Neoplasia; 2005 Mar; 7(3):207-23. PubMed ID: 15799821
[TBL] [Abstract][Full Text] [Related]
16. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
18. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase.
Yin S; Li X; Meng Y; Finley RL; Sakr W; Yang H; Reddy N; Sheng S
J Biol Chem; 2005 Oct; 280(41):34985-96. PubMed ID: 16049007
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth.
Watanabe M; Nasu Y; Kashiwakura Y; Kusumi N; Tamayose K; Nagai A; Sasano T; Shimada T; Daida H; Kumon H
Hum Gene Ther; 2005 Jun; 16(6):699-710. PubMed ID: 15960601
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
Bonfil RD; Sabbota A; Nabha S; Bernardo MM; Dong Z; Meng H; Yamamoto H; Chinni SR; Lim IT; Chang M; Filetti LC; Mobashery S; Cher ML; Fridman R
Int J Cancer; 2006 Jun; 118(11):2721-6. PubMed ID: 16381009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
